Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

NCT01410890 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT01410890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01410890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Completed
Start date
November 3, 2014
Completion date
November 20, 2020
Enrollment
21 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glycogen storage disease type ii (gsd ii), pompe disease